• IMMUNE NETWORK
• /
• 제12권2호
• /
• pp.66-69
• /
• 2012

The immunological death induction by EY-6 on the human tumor cell lines was screened. Human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cells were died by EY-6 treatment with dose-dependent manner. CRT expression, a typical marker for the immunological death, was increased on the EY-6-treated colorectal and gastric cancer cells. Interestingly, the effects on the myeloma cell lines were complicated showing cell line dependent differential modulation. Cytokine secretion from the EY-6 treated tumor cells were dose and cell-dependent. IFN-${\gamma}$ and IL-12 secretion was increased in the treated cells (200% to over 1000% of non-treated control), except HCT116, SNU668 and KMS26 cells which their secretion was declined by EY-6. Data suggest the potential of EY-6 as a new type of immuno-chemotherapeutics inducing tumor-specific cell death. Further studies are planned to confirm the efficacy of EY-6 including in vivo study.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권11호
• /
• pp.6241-6243
• /
• 2013

Objective: To explore the predictive value of tumor markers, including cancer antigen 72-4 (CA72-4), cancer antigen 15-3 (CA15-3) and cancer antigen 125 (CA125), in single or combined detection, for the diagnosis of ovarian cancer. Methods: 120 patients diagnosed with ovarian cancer from August 2011 to March 2013 and 80 patients diagnosed with benign ovarian tumors were enrolled in this test, along with 50 health examination women randomly selected from the database as controls. Serum levels of CA72-4, CA15-3 and CA125 in this study were determined by electrochemiluminescence (ECL). Results: Serum levels of CA72-4, CA15-3 and CA125 in ovarian cancer were higher than those in healthy group and benign group (P<0.01).The sensitivity of combined detection of those three tumor markers for diagnosis of ovarian cancer was obviously higher than with single detection with each marker (P<0.01). Conclusions: CA72-4, CA15-3 and CA125 could be a good combination in the diagnosis of ovarian cancer. Patients whose tumor markers continue to increase should be highly suspected of malignancy.

• BMB Reports
• /
• 제29권5호
• /
• pp.417-422
• /
• 1996

In clonal sublines with different metastatic ability derived from Dunning rat prostate tumor, phosphoamino acid levels of cellular proteins were determined. Cell lines with high metastatic ability exhibited 5-fold higher phosphotyrosine level than did cell lines with low metastatic ability, while the contents of phosphoserine and phosphothreonine were similar among cell lines examined, All cell lines showed similar activities of protein tyrosine kinases as well as overall protein kinases. Phosphotyrosine protein phosphatase (PTPP) activities of the cells with high metastatic ability were very low, compared to those of the cells with low metastatic ability, suggesting that the different phosphotyrosine levels among the cell lines were due to the difference in PTPP activities rather than protein tyrosine kinase activities. Cellular activities of prostatic acid phosphatase (PAcP), which has been reported to possess phosphotyrosine protein phosphatase activity, were shown to be inversely related to the phosphotyrosine levels and metastatic abilities of the prostate tumor cells, These results suggest that cellular PAcP activity, regulating phosphotyrosine levels of cellular proteins, is closely connected with the metastatic process in prostate tumor cells and can be utilized as a good biochemical marker for the diagnosis of metastasis of prostate tumor.

• Asian-Australasian Journal of Animal Sciences
• /
• 제22권10호
• /
• pp.1359-1365
• /
• 2009

We performed a genome-wide linkage and quantitative trait locus (QTL) analysis to confirm the existence of QTL affecting Rous Sarcoma Virus (RSV) induced tumor regression, and to estimate their effects on phenotypic variance in an F2 resource population. The F2 population comprised 158 chickens obtained by crossing tumor regressive White Leghorn (WL) and tumor progressive Rhode Island Red (RIR) lines was measured for tumor formation after RSV inoculation. Forty-three tumor progressive and 28 tumor regressive chickens were then used for genome-wide linkage and QTL analysis using a total of 186 microsatellite markers. Microsatellite markers were mapped on 20 autosomal chromosomes. A significant QTL was detected with marker LEI0258 located within the MHC B region on chromosome 16. This QTL had the highest F ratio (9.8) and accounted for 20.1% of the phenotypic variation. Suggestive QTL were also detected on chromosomes 4, 7 and 10. The QTL on chromosome 4 were detected at the 1% chromosome-wide level explaining 17.5% of the phenotypic variation, and the QTLs on chromosome 7 and 10 were detected at the 5% chromosome-wide level and explained 11.1% and 10.5% of the phenotypic variation, respectively. These results indicate that the QTLs in the non-MHC regions play a significant role in RSV-induced tumor regression. The present study constitutes one of the first preliminary reports in domestic chickens for QTLs affecting RSV-induced tumor regression outside the MHC region.

• Asian Pacific Journal of Cancer Prevention
• /
• 제13권3호
• /
• pp.857-860
• /
• 2012

Serum tumor marker CA15-3 is widely used in follow-up for assessment of breast cancer prognosis. The aim of this study was to evaluate levels among healthy females and patients, to assess differences with tumor stage and grade, and to determine the relationship with estrogen and progesterone receptor expression. One hundred and thirty six Jordanian females were enrolled in this study: Forty-five were healthy females; seventy-two were diagnosed with breast cancer and nineteen diagnosed with benign breast lesions. Elevated serum CA15-3 level was significantly observed among breast cancer patients ($37.95{\pm}6.65$) compared to both healthy ($14.97{\pm}0.8$) and benign females ($12.30{\pm}1.55$), but no significant association was detected between serum CA15-3 level and age of cancer onset, menarche age, menopause age, parity and BMI. Decreased CA15-3 level was significantly associated with hormone therapy and oral contraceptive consumption among breast cancer patients. Significantly elevated CA15-3 serum levels were found among grade II, III and stage II and III breast cancer females compared to normal healthy females. Elevated CA15-3 serum levels were also found among ER+/PR+($54.242{\pm}7.89$) and ER+/PR-($37.08{\pm}8.22$) compared to healthy control females.

• Journal of Veterinary Science
• /
• 제22권6호
• /
• pp.79.1-79.14
• /
• 2021

Background: In contrast to human medicine, only a small number of serum tumor markers are established in veterinary medicine even though they are a non-invasive diagnostic tool. Objectives: This study examined whether survivin could be suitable as a potential canine serum tumor marker. Methods: This study measured the serum survivin concentrations of dogs with mammary tumors (n = 33), squamous cell carcinoma (n = 9), soft-tissue sarcoma (n = 18) and multicentric lymphoma (n = 22), using a commercially available, competitive immunoassay kit (BlueGene). The serum survivin concentrations were compared with those of a healthy control group (n = 20) and a control group of dogs with non-neoplastic diseases (n = 17). Results: Dogs with malignant tumors had serum survivin concentrations between 15 and 5,906 pg/mL (median, 72 pg/mL), those in the healthy group ranged from 7 to 99 pg/mL (median, 21 pg/mL) and those in the group of dogs suffering from non-neoplastic diseases from 15 to 93 pg/mL (median, 42 pg/mL). The differences in the survivin concentrations between the healthy dogs and dogs with malignant tumors and between the dogs with non-neoplastic diseases and those with malignant tumors were significant (p < 0.001 and p = 0.006, respectively). Conclusions: The serum survivin concentrations in dogs with malignant tumors, with some exceptions, are higher than in dogs with benign tumors and dogs that do not suffer from a malignancy. Therefore, survivin can provide information on the presence of malignant tumors and be used as a tumor marker in dogs.

• Journal of Gastric Cancer
• /
• 제4권4호
• /
• pp.235-241
• /
• 2004

목적: 위암의 혈청 종양표지자인 CEA, CA 19.9, CA 72-4가 위암의 수술 전 평가 및 수술 후 재발 감시에 있어서 유용성이 있는지의 여부를 알아보기 위하여 본 연구를 시행하였다. 대상 및 방법: 1995년부터 2000년까지 위암으로 근치적 위절제술을 시행 받은 환자 중 수술 전, 수술 후 2주 그리고 6개월 간격의 추적 관찰 기간 동안 혈청 CEA, CA 19-9, CA 72-4 검사가 시행되었던 환자 255명을 대상으로 후향적 연구를 시행하였다. 종양표지자의 정상 참고치는 CEA의 경우 5 ng/ml, CA 19-9의 경우 36 U/ml, CA 72-4의 경우 4 U/ml로 하였다. 병기는 UICC TNM 병기분류법 제 5판에 준하여 분류하였다. 결과: 각 종양표지자의 수술 전 양성률은 CEA $10.5\%$, CA 19-9 $9.7\%$, CA 72-4 $12.4\%$였고, 세 종양표지자 모두 근치수술 후 혈청치가 감소하였다. CEA가 종양크기와 통계적인 연관성이 없는 것을 제외하고, 세 종양표지자의 수술 전 혈청치는 종양침윤깊이, 종양크기, 림프절 전이, 병기 그리고 재발과 의의있는 연관성이 있었다. 재발 환자에 있어서 종양표지자의 민감도는 CEA $43.3\%$, CA 19-9 $41.8\%$, CA 72-4 $50.0\%$였고, 특이도는 CEA $85.1\%$,CA 19-9 $96.8\%$, CA 72-4 $87.8\%$였다. 결론: CEA,CA19-9, CA 72-4의 수술 전 혈청치는 낮은 양성률 때문에 위암의 초기 진단에 유용성이 낮다. 그렇지만 수술 전 혈청치의 양성률이 종양침윤깊이, 림프절 전이, 종양크기, 병기, 재발과 연관성이 있고, 또한 수술 후 추적 관찰 중에 측정한 세 종양표지자의 혈청치도 비록 민감도는 낮지만 재발과 통계적으로 의의있는 연관성이 있다는 점을 고려해야한다.

• Nuclear Medicine and Molecular Imaging
• /
• 제42권3호
• /
• pp.201-208
• /
• 2008

목적; 복부 전산화단층촬영(CT) 및 종양표지자와 비교를 통하여 자궁경부암 및 난소암의 재발을 진단하고 치료에 대한 반응을 평가하는데 FDG를 이용한 양전자단층촬영(PET)이 어떤 역할을 하고 있는지 알아보고 앞으로 환자의 주요 추적검사방법이 될 수 있는지에 대해 알아보고자 하였다. 대상 및 방법; 2006년 5월 1일부터 2007년 10월 31일 사이에 FDG-PET를 시행한 환자 중 비슷한 시기에 복부 CT를 시행 받은 67명 환자 103예를 대상으로 하였다(자궁경부암 42예, 난소암 51예). PET, CT 및 혈중 종양표지자에 대한 판독을 후향적으로 서로 비교하였다. 세 검사에서 모두 양성을 보이거나 추적검사상 병변이 커지거나 조직검사 및 기타 검사에서 양성을 보일 때를 재발이라고 정의하여 세 검사방법의 판독에서의 차이를 분석하였다. 자궁경부암군과 난소암군으로 나누어 PET와 복부 CT 종양 표지자에 대한 진단의 민감도, 특이도, 양성 및 음성예측도를 알아보았다. 결과; 재발로 진단된 예는 37예였다. 자궁경부암에서 재발로 진단되었던 경우가 11예(9명)였으며 민감도는 각각 100%(11/11), 54.5%(6/11), 81.1%(9/11)로 PET가 가장 높았고, 특이도는 각각 93.6%(29/31), 93.6%(29/31), 100% (31/31)로 종양표지자가 가장 높았다. 난소암의 재발 진단은 26예(15명)였으며 민감도는 각각 96.2%(25/26), 84.6% (22/26), 80.8%(21/26)로 PET가 가장 높았고, 특이도는 세 검사에서 94.3%(33/35)로 동일하였다. CT에 비하여 PET에서 복강내 전이를 6예를 더 진단하였고 4예의 종격동임파절 및 폐전이를 더 진단할 수 있었으며 2예의 쇄골상와임파절과 1예의 액와임파절의 전이를 더 진단하였다. 재발환자의 분석에서 PET는 복부 외 장기의 재발을 발견할 수 있었고 복부내 재발의 경우에도 CT보다 더 민감하게 재발부위를 찾을 수 있었던 반면 CT의 도움 없이는 정확한 위치 측정이 어려웠다. CT는 잔여종양과 양성섬유화의 구분 및 조직간의 경계부위에서 종양의 구분이 어려웠고 복부 이외 장기의 전이를 발견할 수 없었다. 결론; PET는 자궁경부암과 난소암 진단에서 CT에 비해 적용 부위가 크고 조직 대조도가 커 민감도가 높은 검사법으로서 치료 후 잔여 종양의 여부나 재발을 진단하는 데 필수적이 검사법이 될 것으로 사료된다.

• 대한의생명과학회지
• /
• 제5권2호
• /
• pp.181-190
• /
• 1999

한국인의 대표적인 성인 고형 종양인 위암, 간암, 유방암과 소아 백혈병 및 2종의 소아 고형 종양 환자로부터 혈장 transforming growth factor-$\beta$1 (TGF-$\beta$1) 농도를 sandwich ELISA 분석법을 이용해 측정함으로써 TGF-$\beta$1을 이 질환들에 대한 새로운 종양표지자 (tumor marker)로 사용할 수 있는지 검토하였다. 토한 연령 및 성별에 따른 혈장 TGF-$\beta$1 농도의 정상치를 조사하였다. 신생아에서 70대까지 혈장 TGF-$\beta$1 농도의 차이는 없었고 남녀간의 차이도 없었다. 위암 환자의 혈장 TGF-$\beta$1 농도는 16.0$\pm$6.8 ng/ml (평균$\pm$표준편차)로 정상 대조군의 TGF-$\beta$1 농도 (8.3$\pm$5.0 ng/ml) 보다 유의하게 높았으나 간암, 유방암 환자의 혈장 TGF-$\beta$1 농도는 대조군과 차이가 없었다. 그리고 위암 환자 16명 ,간암 환자 8명, 유방암 환자 7명 중 각각 7명 (43.7%), 1명 (12.5%), 1명 (14.3%)에서만 혈장 TGF-$\beta$1 농도가 증가되었다. 5명의 소아 백혈병 환자에서는 관해 (remission)여부와 상관없이 혈장TGF-$\beta$1농도가 모두 정상 범위에 있었으나 2명의 소아 고형암 환자에서는 종양 절제 전에는 혈장 TGF-$\beta$1농도가 높았다가 절제 후 정상으로 떨어졌다. 결론적으로 1)정상인의 혈장 TGF-$\beta$1 농도는 연령 및 성별에 따른 차이가 없다는 것을 알 수 있었고, 2)성인 고형암인 위암, 간암, 유방암에서는 낮은 민감도로 인해 TGF-$\beta$1을 진단을 위한 선별 검사로 이용하기에는 부적절한 것으로 판단되었으며, 3)정상 대조군보다 혈장 TGF-$\beta$1 농도가 높았던 위 암 환자와 종양 절제 전후로 혈장 TGF-$\beta$1 농도가 민감하게 변했던 소아 고형암 환자에 대 해서는 향후 표본 수를 늘려 부가적인 연구를 해야 할 것으로 사료된다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권12호
• /
• pp.4933-4938
• /
• 2014

Background: Although various tumor markers have been utilized in management of stomach cancer (SC), only a few reports have described relevance of examples such as CYFRA 21-1 and neuron-specific enolase (NSE). The purpose of this study was to evaluate the potential diagnostic performance of carcinoembryonic antigen (CEA), CA 19-9, CA72-4, CYFRA 21-1 and NSE in patients with SC. Materials and Methods: Ninety-six SC patients with pathologic confirmation between 2012 and 2013 were enrolled. Serum levels of five tumor markers were analyzed using a solid-phase immunoradiometric assay. Receiver operating characteristic (ROC) curves were plotted for the five tumor markers to investigate their diagnostic powers and adjusted cutoff values derived from analysis of ROC curves were evaluated to calculate the sensitivity of each for SC with recommended cutoff values. Results: Based on two different cutoff values (recommended and adjusted), CYFRA 21-1 (${\geq}2.0$ and 1.2 ng/ml) had a respective sensitivity of 50% and 78.1%, compared with 8.3% and 18.8% for CEA (${\geq}7.0$ and 3.9 ng/ml), 15.6% and 18.8% for CA 19-9 (${\geq}37$ and 26.7 ng/ml), 28.1% and 9.6% for CA 72-4 (${\geq}4.0$ and 13 ng/ml) and 7.3% and 7.3% for NSE (${\geq}14.7$ and 15.0 ng/ml) in the initial staging of primary SC. The area under the curve (AUC) for CYFRA 21-1, with a value of 0.978 (95% confidence interval, 0.964-0.991) was comparatively the highest. Univariate analysis revealed significant relationships between tumor marker level and lymph node involvement, metastasis and staging with CYFRA 21-1, CA 72-4 and NSE. Conclusions: CYFRA 21-1 was the most sensitive tumor marker and showed the most powerful diagnostic performance among the five SC tumor markers. NSE and CA 72-4 are significantly related to lymph node involvement, metastasis or stage. Further evaluations are warranted to clarify the clinical usefulness and prognostic prediction of these markers in SC.